Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 2,500 Shares

Key Points

• Gilead Sciences CFO Andrew Dickinson sold 2,500 shares of the company's stock for a total of $283,925, resulting in a 1.54% decrease in his ownership position.
• The company reported $2.01 earnings per share (EPS) for its latest quarter, surpassing expectations, with revenue reaching $7.08 billion.
• Gilead Sciences announced a quarterly dividend of $0.79 per share, corresponding to a 2.9% dividend yield, with the payout scheduled for September 29th.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gilead Sciences Price Performance

Shares of GILD traded down $1.68 during mid-day trading on Tuesday, hitting $110.86. The company's stock had a trading volume of 5,457,797 shares, compared to its average volume of 8,084,145. The firm has a 50-day moving average price of $114.05 and a 200 day moving average price of $110.06. The stock has a market capitalization of $137.56 billion, a price-to-earnings ratio of 22.08, a PEG ratio of 0.78 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a fifty-two week low of $81.83 and a fifty-two week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Institutional Investors Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in GILD. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences during the 1st quarter worth about $25,000. Activest Wealth Management grew its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 227 shares during the last quarter. GoalVest Advisory LLC grew its holdings in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences during the 2nd quarter worth about $27,000. Finally, Goodman Advisory Group LLC bought a new stake in Gilead Sciences during the 1st quarter worth about $29,000. Institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the subject of several recent analyst reports. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday. Finally, Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $116.04.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.